Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux versus low molecular weight heparin after primary PCI in acute myocardial infarction
ChiCTR1900023824Phase 4Not yet recruiting
- Sponsor
- Shanxi Provincial Hospital of Cardiovascular Diseases
- Start
- Jun 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux and low molecular weight heparin calcium in myocardial infarction (MI) (2 arms), sponsored by Shanxi Provincial Hospital of Cardiovascular Diseases. Primary endpoint: 30-day net adverse clinical events. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
fondaparinuxlow molecular weight heparin calcium
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR1900023824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023824.